Form 4: United Therapeutics CFO Sells Shares Via 10b5-1 Plan
Insider Transaction Report
United Therapeutics Corp. CFO and Treasurer James Edgemond executed a Rule 10b5-1 trading plan, resulting in the sale of 10,000 shares of common stock.
Summary
- James Edgemond, CFO and Treasurer of United Therapeutics Corp., reported transactions on May 26, 2026.
- These transactions involved the exercise of 10,000 stock options at an exercise price of $117.76 per share.
- Following the option exercise, Edgemond sold these shares, with the weighted average sale price reported at $566.3667.
- The sales were conducted through a Rule 10b5-1 trading plan established on October 31, 2025, which is designed to satisfy affirmative defense conditions.
- The total number of shares beneficially owned by Edgemond after these transactions is 18,876.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine insider transactions conducted under a pre-established trading plan, which is a standard practice for executives.
Negatives
- The CFO sold a significant number of shares (10,000) acquired through option exercises.
Future Outlook
The filing does not contain forward-looking statements or guidance. It reports on past transactions.
Management Comments
- The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Industry Context
StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are common for executives to diversify holdings or manage personal finances. The timing and volume of such sales can be scrutinized by investors for potential insights into management's view of the company's valuation.
Stakeholder Impact
- Shareholders may view the sale of shares by a key executive with scrutiny, although the use of a Rule 10b5-1 plan mitigates concerns about insider trading based on material non-public information.
Key Dates
| Date | Description |
|---|---|
| 10/31/2025 | Date the Rule 10b5-1 trading plan was entered into by the reporting person. |
| 03/15/2023 | Date exercisable for the stock option. |
| 03/15/2027 | Expiration date for the stock option. |
| 05/26/2026 | Date of the reported transactions (exercise of stock options and sale of common stock). |
| 05/27/2026 | Date of signature for the filing. |
Keywords
Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, Rule 10b5-1, Insider Trading, Beneficial Ownership, CFO, Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.